Prof. Tony Mok and Prof. Giorgio Scagliotti
Chinese University of Hong Kong, China and University of Torino, Italy
PD-1 inhibitors for NSCLC: Where are we now?
Prof. Tony Mok welcomes you to this ESMO Virtual Congress 2020 Satellite Symposium exploring PD-1 inhibitors on the horizon in NSCLC. After walking us through the agenda, Prof. Mok provides an update on the current status of immunotherapy regimens incorporating PD-1 blockade in NSCLC, contextualizing the clinical value of PD-L1 expression thresholds and appraising potential implications for single-agent and combination treatment strategies.view bio and disclosures 1/6 Next Chapter
One molecule, many mechanisms of action: Why all PD-1 inhibitors are not the same
Dr Raffaele Califano provides a mechanistic overview of the ‘new wave’ of PD-1 inhibitors now emerging in the immunotherapy landscape. Summarizing key preclinical and early phase data, Dr Califano reflects on the safety and efficacy of these new agents in light of their structural and mechanistic differences.view bio and disclosures 2/6 Next Chapter
How will the new wave of PD-1 inhibitors change the treatment landscape in NSCLC?
Prof. Anne-Marie Dingemans talks us through recently published safety and efficacy data from Phase II/III studies investigating this ‘new wave’ of PD-1 inhibitors in advanced lung cancer. Reflecting on these latest clinical trial results, Prof. Dingemans explores the potential impact of these new agents on the NSCLC treatment paradigm.view bio and disclosures 3/6 Next Chapter
PD-1 inhibitors in NSCLC: A case discussion
Profs. Tony Mok and Anne-Marie Dingemans engage in a lively and informative case study discussion, sharing their experiences from clinical practice and evaluating the rationale for clinical decision-making relating to treatment selection with immunotherapies. The professors also touch upon the recent implications of COVID-19 for clinical management of patients with NSCLC.view bio and disclosures 4/6 Next Chapter
PD-1 inhibitors for NSCLC: Future challenges, future potential
Prof. Giorgio Scagliotti draws upon existing clinical understanding and emerging scientific concepts in cancer immunotherapy to assess what tools are needed to further optimize PD-1 blockade in NSCLC. Characterization of the complex network of relevant biomarkers and robust definitions of hyper-progressive disease are explored as key unmet needs still to be addressed. After summarizing the key themes from this ESMO Virtual Congress 2020 Satellite Symposium, Prof. Scagliotti thanks his fellow presenting faculty before closing the meeting.view bio and disclosures 5/6 Next Chapter
Live Q&A Session recorded at the ESMO Virtual Congress 2020
Following on from this engaging Satellite Symposium, Prof. Tony Mok and Prof. Scagliotti co-chair an informative Q&A session with panelists Dr Raffaele Califano and Prof. Anne-Marie Dingemans. Our panel of expert faculty appraise the very latest data surrounding immunotherapy in NSCLC presented at the ESMO Virtual Congress 2020, and explore potential implications for future clinical practice and patient management.view bio and disclosures 6/6 Leave Feedback
Overview & Learning Objectives
In this activity, Professors Tony Mok and Giorgio Scagliotti co-chair an informative Satellite Symposium at the ESMO Virtual Congress 2020 (19–21 September 2020) exploring recent developments in non-small cell lung cancer (NSCLC) treatment strategies incorporating programmed cell death protein-1 (PD-1) blockade. This includes a discussion with Dr Raffaele Califano and Professor Anne-Marie Dingemans, appraising the latest data on new and emerging PD-1 inhibitors and contextualising their potential impact on the immunotherapy landscape for NSCLC.
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, involved in the clinical management of patients with NSCLC.
After watching this activity participants should be better able to:
- Review the latest clinical and pre-clinical data for anti-PD-1 agents in NSCLC
- Discuss how current and emerging anti-PD-1 agents may be incorporated into the treatment landscape for NSCLC
- Summarize how to identify the patients most suitable for anti-PD-1 blockade
Faculty & Disclosures
Prof. Tony Mok
Chinese University of Hong Kong, Hong Kong, China
Professor Tony Mok trained at the University of Alberta, Canada before completing a fellowship in medical oncology at the Princess Margaret Hospital, Toronto, Canada. After working as a community oncologist in Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career. He currently holds the Li Shu Fan Medical Foundation endowed Professorship and chairs the Department of Clinical Oncology at the Chinese University of Hong Kong, China.
His main research interests focus on biomarker discovery and molecular-targeted therapies in lung cancer, and he has published extensively in leading peer-reviewed journals.
Professor Mok is actively engaged in clinical research, leading several landmark trials as Principal Investigator.
His work has been incorporated into multiple international guidelines including the NCCN, AMP/IASLC/CAP, ASCO and ESMO clinical guidelines. He also contributes to the development of clinical research infrastructure in China and Asia. He co-founded the Lung Cancer Research Group, the Chinese Thoracic Oncology Research Group and the Asia Thoracic Oncology Research Group. He is the Past President and Past Treasurer of the IASLC. He is a member of the Board of Directors for ASCO, AstraZeneca, Sanomics and Hutchison Chi-Med. He is active in international medical education initiatives and has made significant contributions to the AACR, ASCO, CSCO and ESMO programmes.
Disclosures: Board of Directors for AstraZeneca PLC; Hutchison China MediTech, Sanomics Limited. Consultant/advisory boards for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Clovis Oncology, Merck Serono, Merck Sharp & Dohme, Novartis, SFJ Pharmaceuticals, ACEA Biosciences, Vertex Pharmaceuticals, Bristol-Myers Squibb, geneDecode, OncoGenex, Celgene, Ignyta, Cirina. Grants, personal fees and other from AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmaceuticals, Roche/Genentech, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Eisai, Taiho Pharmaceutical Co., Ltd.
Prof. Giorgio Scagliotti
University of Torino, Turin, Italy
Giorgio Scagliotti is a Full Professor of Medical Oncology at the University of Torino, Italy, where he earned his medical degree and completed postgraduate training in respiratory medicine, internal medicine and medical oncology. He is currently Chief of the Medical Oncology Division at the San Luigi Hospital, Orbassano, Italy and is also a Member of the Administrative Board of the University of Torino, Italy. Professor Scagliotti has held prominent positions at the University of Torino, including Head of the Department of Oncology (2012–2017) and Chairperson of the Postgraduate School in Respiratory Medicine (2007–2012).
Over the last 15 years, Professor Scagliotti’s research interests have included experimental studies encompassing basic and clinical applied research in lung cancer, including translational research. He has been the study coordinator for several European and international clinical trials investigating chemotherapy and targeted therapies in lung cancer; notably, several key Italian studies investigating the role of chemotherapy in early stage NSCLC. Professor Scagliotti served as President of the IASLC from 2017 to 2019.
Disclosures: Consultant/advisory boards for AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche.
Dr Raffaele Califano
The Christie NHS Foundation Trust, Manchester, UK
Dr Raffaele Califano works as a Consultant Medical Oncologist at The Christie Hospital and University of Manchester Hospital, both in Manchester, UK. He is also an Honorary Senior Lecturer in Cancer Sciences at the University of Manchester. Dr Califano has a specialist interest in thoracic malignancies and clinical cancer research, and is an active member of the Manchester Lung Cancer Group. He graduated in Medicine and Surgery, summa cum laude, from the University of Perugia, Italy in 2003 and completed his Specialist Training in Medical Oncology in 2007.
Dr Califano worked for four years as Clinical Research Fellow with the Lung and Melanoma Team at The Christie Hospital and has been an investigator for several Phase Ib–III clinical trials, developing a particular interest for molecularly driven clinical trials in advanced NSCLC, SCLC and mesothelioma.
Dr Califano’s research focus encompasses immunotherapy and oncogene-driven lung cancer. He serves as a member of the ESMO Educational Publishing Working Group, and is also a member of BTOG and IASLC. Dr Califano is the author of several papers published in indexed peer-reviewed international journals and he has been an invited speaker to several national and international oncology meetings.
Disclosures: Grants/research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Clovis, Lilly Oncology, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda. Consultant/advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly Oncology, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda. Stock ownership with The Christie Private Care.
Professor Anne-Marie Dingemans
Erasmus Medical Center, Rotterdam, The Netherlands
Anne-Marie Dingemans is Professor of Pulmonology with a specialist interest in thoracic oncology, based at the Erasmus Medical Center, Rotterdam, The Netherlands. Between 2004 and 2019, she served as a staff member in the Department of Pulmonology at the Maastricht University Medical Center. After earning her medical degree from Maastricht University in 1994, Professor Dingemans subsequently gained her PhD in 2000 from VU Medical Center, Amsterdam, for laboratory research investigating resistance to chemotherapy in lung cancer. She completed her training as a pulmonologist at VU Medical Center in Amsterdam and Leiden University Medical Center.
Currently, Professor Dingemans is actively involved in translational research in lung cancer, with special interests in neuroendocrine lung tumours, driver mutations and oligometastatic disease. She is secretary of the EORTC lung cancer group and was involved in the EORTC initiative to develop a consensus definition on synchronous oligometastatic NSCLC. Furthermore, she is a member of AACR, ASCO, ERS, ESMO, ETOP and IASLC. She has (co)-authored more than 200 publications and book chapters.
Disclosures: Grants/research support from AbbVie, Amgen, Bristol-Myers Squibb. Consultant/advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pharmamar, Roche, Takeda.